Chronic Diseases Pharmacology Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
ChemMedChem. 2021 Jan 8;16(1):179-186. doi: 10.1002/cmdc.202000454. Epub 2020 Aug 25.
This study explores the potential of 7-amidocoumarins as multitarget agents against Parkinson's and Alzheimer's diseases, by modulating the substitution patterns within the scaffold. Sixteen compounds were synthesized via 7-amino-4-methylcoumarin acylation, and in vitro evaluation of the molecules against hMAO-A, hMAO-B, hAChE, hBuChE and hBACE1 was performed. Five compounds turned out to be potent and selective hMAO-B inhibitors in the nanomolar range, six displayed inhibitory activity of hMAO-A in the low micromolar range, one showed hAChE inhibitory activity and another one hBACE1 inhibitory activity. MAO-B reversibility profile of 7-(4'-chlorobenzamido)-4-methylcoumarin (10) was investigated, with this compound being a reversible inhibitor. Neurotoxicity on motor cortex neurons and neuroprotection against H O were also studied, corroborating the safety profile of these molecules. Finally, theoretical ADME properties were also calculated, showing these molecules as good candidates for the optimization of a lead compound. Results suggest that by modulating the substitution pattern at position 7 of the scaffold, selective or multitarget molecules can be achieved.
本研究通过调节支架上的取代模式,探索了 7-氨基香豆素作为治疗帕金森病和阿尔茨海默病的多靶标药物的潜力。通过 7-氨基-4-甲基香豆素酰化合成了 16 种化合物,并对这些分子在体外对 hMAO-A、hMAO-B、hAChE、hBuChE 和 hBACE1 的抑制活性进行了评价。有 5 种化合物在纳摩尔范围内对 hMAO-B 表现出很强的抑制作用和选择性,有 6 种化合物在低微摩尔范围内对 hMAO-A 具有抑制活性,有 1 种化合物对 hAChE 具有抑制活性,有 1 种化合物对 hBACE1 具有抑制活性。还对 7-(4'-氯苯甲酰胺基)-4-甲基香豆素(10)的 MAO-B 可逆性进行了研究,发现该化合物为可逆抑制剂。还研究了对运动皮层神经元的神经毒性和对 H2O2 的神经保护作用,证实了这些分子的安全性。最后,还计算了理论 ADME 性质,表明这些分子是优化先导化合物的良好候选物。结果表明,通过调节支架上 7 位的取代模式,可以得到选择性或多靶标分子。